Independent
Tenure on this board
2.9 yrs
Also a director at
Spyre Therapeutics Inc (SYRE)Perceptive Capital Solutions Corp (PCSC)Newamsterdam Pharma Co NV (NAMS)Helix Acquisition Corp III (HLXC)
Meeting calendar
APGE · Annual meeting · Tuesday, June 9, 2026
Apogee Therapeutics Inc
3 nominees · 3 ballot items.
Elect three Class III directors; ratify Ernst & Young LLP as independent auditor; approve, on a non-binding advisory basis, executive compensation (Say-on-Pay).
Market cap
$10.1B
1Y TSR
+214.7%
Board grade
B
Record date
Apr 15, 2026
Filing
DEF 14A
Meeting concluded · Jun 9, 2026
Follow how the vote landed and what changed on Apogee Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect three Class III director nominees (Mark C. McKenna, Jennifer Fox, William (BJ) Jones, Jr.) to serve until the 2029 Annual Meeting.
- 2
Ratification of Independent Auditor Appointment
ManagementBoard: FORRatify appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
More detail
The Audit Committee proposes ratification of EY as the independent auditor for 2026. While not required, stockholder ratification is sought as best practice; EY has served since 2023. The proxy discloses fees and the Audit Committee’s pre-approval policies. A ratification vote gives the Committee affirmation but does not bind it from changing auditors if necessary. The Board recommends a vote FOR based on the committee’s review of EY’s qualifications, independence, and audit services. This proposal is routine and governance-focused, with low controversy and limited substantive strategic impact beyond auditor oversight.
- 3
Advisory Vote on Executive Compensation (Say-on-Pay
ManagementBoard: FORNon-binding, advisory approval of the compensation of the named executive officers as disclosed in the Proxy Statement.
More detail
This management-sponsored Say-on-Pay proposal seeks a non-binding advisory approval of the named executive officers’ compensation as disclosed. It reflects the Board’s view that compensation is linked to performance, with a heavy at-risk mix (bonuses and options) and multi-year vesting. The Compensation Committee used market peer data, an independent consultant, and pay-for-performance metrics tied to clinical and financial milestones in setting pay. The proposal is routine but meaningful as a governance signal; the Board commits to consider the vote outcome in future decisions. The recommendation is FOR, supported by disclosure of pay practices, clawback policy, and severance and change-in-control protections. Potential stockholder concerns could include high realized pay in recent years and the use of staggered board and classified governance provisions, but the Company emphasizes alignment via substantial equity-based, performance-linked awards.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
3.1 yrs
Also a director at
Prokidney Corp (PROK)
Independent
Tenure on this board
3.0 yrs
Also a director at
Annexon Inc (ANNX)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 13.7% | 10,300,984 | $867M |
| 2 | Venrock Adviser, LLC | 11.3% | 8,493,321 | $715M |
| 3 | FMR LLC | 8.4% | 6,346,847 | $534M |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 5.2% | 3,944,119 | $332M |
| 5 | FMR LLC | 3.7% | 2,814,085 | $237M |
| 6 | RTW INVESTMENTS, LP | 3.7% | 2,782,097 | $234M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 2,502,095 | $211M |
| 8 | JANUS HENDERSON GROUP PLC | 3.1% | 2,337,628 | $197M |
| 9 | STATE STREET CORP | 2.9% | 2,162,964 | $182M |
| 10 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.5% | 1,920,800 | $162M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Apogee Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.2B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Reference
Frequently asked questions
- When is the Apogee Therapeutics Inc 2026 annual meeting?
- Apogee Therapeutics Inc (APGE) holds its 2026 annual shareholder meeting on Tuesday, June 9, 2026.
- What is the record date for the Apogee Therapeutics Inc 2026 meeting?
- The record date for the Apogee Therapeutics Inc 2026 meeting is Wednesday, April 15, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Apogee Therapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Apogee Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Apogee Therapeutics Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Apogee Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.